Patents by Inventor David A. Bullough

David A. Bullough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240307363
    Abstract: The present invention concerns liquid, dry powder and metered-dose formulations for therapeutic inhaled delivery of ALK5 (TGF-?R1) inhibitor containing compositions to desired anatomical sites, for treatment or prophylaxis of a variety of pulmonary disease conditions such as Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, scleroderma-associated interstitial lung disease, sarcoidosis, cystic fibrosis, lung cancer, and a COVID infection.
    Type: Application
    Filed: May 3, 2022
    Publication date: September 19, 2024
    Applicant: Thirona Bio, Inc.
    Inventors: David A. BULLOUGH, John Gordon FOULKES, Nigel R.A. Beeley, Roger Crystal
  • Publication number: 20240189275
    Abstract: The present invention concerns compositions and methods for treating a patient with non-alcoholic steatohepatitis (NASH) by administration, particularly topical administration, of a pharmaceutical composition comprising a therapeutically effective amount of a stearoyl-CoA desaturase (SCD-1) inhibitor. In certain preferred embodiments, the method prevents the development or progression of, or reduces the extent of, liver fibrosis in the patient.
    Type: Application
    Filed: February 18, 2022
    Publication date: June 13, 2024
    Applicant: Lipidio Pharmaceuticals, Inc.
    Inventors: David A. BULLOUGH, Jonathan David ROTH, John Gordon FOULKES
  • Publication number: 20180312839
    Abstract: Aspects of the disclosure provide compositions or compounds for activating or enhancing expression of SMN. Further aspects provide compositions and kits, e.g., comprising single stranded oligonucleotides, for activating or enhancing expression of SMN that comprises exon 7. Methods for modulating expression of SMN are also provided.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 1, 2018
    Applicant: Translate Bio MA, Inc.
    Inventors: Balkrishen Bhat, David Bullough
  • Patent number: 5864033
    Abstract: Novel compounds which selectively inhibit adenosine kinase and methods of preparing adenosine kinase inhibitors are provided. Also provided are methods of treating various conditions which may be ameliorated by increased local concentrations of adenosine using adenosine kinase inhibitors.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: January 26, 1999
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Clinton E. Browne, Bheemarao G. Ugarkar, Kevin M. Mullane, Harry E. Gruber, David A. Bullough, Mark D. Erion, Angelo Castellino
  • Patent number: 5777100
    Abstract: Analogs of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide (AICA riboside) are provided which are useful in increasing extracellular levels of adenosine.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 7, 1998
    Assignee: Gensia Inc.
    Inventors: David A. Bullough, Harry E. Gruber, Ernest K. Metzker, Kevin M. Mullane, Bheemarao G. Ugarkar, Clinton E. Browne
  • Patent number: 5646128
    Abstract: Novel compounds which selectively inhibit adenosine kinase and methods of preparing adenosine kinase inhibitors are provided. Also provided are methods of treating various inflammatory conditions, including arthritis and SIRS, which may be ameliorated by increased local concentrations of adenosine using adenosine kinase inhibitors.
    Type: Grant
    Filed: December 1, 1994
    Date of Patent: July 8, 1997
    Assignee: Gensia, Inc.
    Inventors: Gary S. Firestein, Bheemarao G. Ugarkar, Leonard P. Miller, Harry E. Gruber, David A. Bullough, Mark D. Erion, Angelo J. Castellino, Clinton E. Browne